NetraMark Holdings Inc. (TSX:AIAI)
1.010
-0.040 (-3.81%)
May 11, 2026, 2:48 PM EDT
NetraMark Holdings Revenue
NetraMark Holdings had revenue of 118.85K CAD in the quarter ending December 31, 2025, a decrease of -69.22%. This brings the company's revenue in the last twelve months to 165.26K, down -80.37% year-over-year. In the fiscal year ending September 30, 2025, NetraMark Holdings had annual revenue of 432.50K, down -5.18%.
Revenue (ttm)
165.26K
Revenue Growth
-80.37%
P/S Ratio
543.80
Revenue / Employee
n/a
Employees
n/a
Market Cap
89.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 432.50K | -23.63K | -5.18% |
| Sep 30, 2024 | 456.13K | 366.86K | 410.97% |
| Sep 30, 2023 | 89.27K | -23.76K | -21.02% |
| Sep 30, 2022 | 113.03K | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vitalhub | 119.20M |
| kneat.com | 63.26M |
| Hydreight Technologies | 35.39M |
| NexgenRx | 17.93M |
| Comprehensive Healthcare Systems | 5.65M |
| Principal Technologies | 370.42K |
| KDA Group | 317.01K |
| AI/ML Innovations | 125.47K |
NetraMark Holdings News
- 5 days ago - NetraMark Announces Change To Board Of Directors - GlobeNewsWire
- 7 days ago - NetraMark Holdings Inc. (AIAI) Opens the Market - Newsfile Corp
- 8 days ago - NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI - GlobeNewsWire
- 12 days ago - NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026 - GlobeNewsWire
- 20 days ago - NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs - GlobeNewsWire
- 22 days ago - Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development - GlobeNewsWire
- 4 weeks ago - Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain - GlobeNewsWire
- 6 weeks ago - NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset - GlobeNewsWire